This report describes a case of Crimean-Congo hemorrhagic fever with widespread hemorrhages and multiple organ dysfunction syndrome in a 46-year-old patient from an endemic region. Although the patient had numerous poor prognostic factors, he was discharged in a healthy condition after 17 days of hospitalization with close monitoring and supportive care. Tranexamic acid was successfully used together with other supportive treatments.

Keywords:
Mortality, Supportive care, Tranexamic acid, Crimean-Congo hemorrhagic fever
1.
Köksal I, Yilmaz G, Iskender S, Arslan M, Yavuz I, Aksoy F, Vatansever Z: The first Crimean-Congo hemorrhagic fever case in the winter season from Turkey. Intervirology 2011;54:144-145.
2.
Papa A, Mirazimi A, Köksal I, Pena AE, Feldmann H: Recent advances in research on Crimean-Congo hemorrhagic fever. J Clin Virol 2015;64:137-143.
3.
Cevik MA, Erbay A, Bodur H, Gülderen E, Baştuğ A, Kubar A, Akinci E: Clinical and laboratory features of Crimean-Congo hemorrhagic fever: predictors of fatality. Int J Infect Dis 2008;12:374-379.
4.
Papa A, Dalla V, Papadimitriou E, Kartalis GN, Antoniadis A: Emergence of Crimean-Congo haemorrhagic fever in Greece. Clin Microbiol Infect 2010;16:843-847.
5.
Leblebicioglu H, Bodur H, Dokuzoguz B, Elaldi N, Guner R, Koksal I, Kurt H, Senturk GC: Case management and supportive treatment for patients with Crimean-Congo hemorrhagic fever. Vector Borne Zoonotic Dis 2012;12:805-811.
6.
Koksal I, Yilmaz G, Aksoy F, Aydin H, Yavuz I, Iskender S, Akcay K, Erensoy S, Caylan R, Aydin K: The efficacy of ribavirin in the treatment of Crimean-Congo hemorrhagic fever in Eastern Black Sea region in Turkey. J Clin Virol 2010;47:65-68.
7.
Keshtkar-Jahromi M, Kuhn JH, Christova I, Bradfute SB, Jahrling PB, Bavari S: Crimean-Congo hemorrhagic fever: current and future prospects of vaccines and therapies. Antiviral Res 2011;90:85-92.
8.
Hunt BJ: The current place of tranexamic acid in the management of bleeding. Anesthesia 2015;70:50-53.
9.
CRASH-2 Trial Collaborators: Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomized, placebo-controlled trial. Lancet 2010;376:23-32.
10.
Kimura S, Odawara J, Aoki T, Yamakura M, Takeuchi M, Watanabe Y, Matsue K: Use of tranexamic acid for disseminated intravascular coagulation with excessive fibrinolysis associated with aortic dissection in a patient with chronic renal failure. Int J Hematol 2009;89:549-552.
11.
Honda M, Matsunaga S, Era S, Takai Y, Baba K, Seki H: Intrapartum anti-disseminated intravascular coagulation therapy leading to successful vaginal delivery following intrauterine fetal death caused by placental abruption: a case report. J Med Case Report 2014;8:461.
12.
Sprigg N, Renton C, Dineed RA, Kwong Y, Bath PM: Tranexamic acid for spontaneous intracranial hemorrhage: a randomized controlled pilot trial. J Stroke Cerebrovasc Dis 2014;23:1312-1318.
13.
Zehtabchi S, Abdel Baki SG, Falzon L, Nishijima DK: Tranexamic acid for traumatic brain injury: a systematic review and meta-analysis. Am J Emerg Med 2014;32:1503-1509.
14.
Fernandez-L A, Garrido-Martin EM, Sanz-Rodriguez F, Ramirez JR, Morales-Angulo C, Zarrabeitia R, Perez-Molino A, Bernabéu C, Botella LM: Therapeutic action of tranexamic acid in hereditary haemorrhagic telangiectasia (HHT): regulation of ALK-1/endoglin pathway in endothelial cells. Thromb Haemost 2007;97:254-262.
15.
Robertshaw HJ: An anti-inflammatory role for tranexamic acid in cardiac surgery? Crit Care 2008;12:105.
16.
Napolitano LM, Cohen MJ, Cotton BA, Schreiber MA, Moore EE: Tranexamic acid in trauma: how should we use it? J Trauma Acute Care Surg 2013;74:1575-1586.
17.
Jansen AJ, Andreica S, Claeys M, D'Haese J, Camu F, Jochmans K: Use of tranexamic acid for an effective blood conservation strategy after total knee arthroplasty. Br J Anaesth 1999;83:596-601.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.